ERBB2 and breast carcinoma: The novelty of the present work lies in the detection andsemi-quantification of four distinct levels of HER2 (0, 1+,2+, 3+) expressions in HER2 control pellet arrays (CPA), andin the demonstration of HER2 mapping in breast cancer tissue slides.